Abstract Pancreatic ductal adenocarcinoma is a leading cause of cancer mortality with a dismal 2-5 % 5-year survival rate. Monotherapy with Gemcitabine has limited success, highlighting the need for additional therapies that enhance the efficacy of current treatments. We evaluated the combination of Gemcitabine and Rosiglitazone, an FDA-approved drug for the treatment of type II diabetes, in an immunocompetent transplantable mouse model of pancreatic cancer. Tumor progression, survival, and metastases were evaluated in immunocompetent mice with subcutaneous or orthotopic pancreatic tumors treated with Pioglitazone, Rosiglitazone, Gemcitabine, or combinations of these. We characterized the impact of high-dose Rosiglitazone and Gemcitabine therapy on immune suppressive mediators, including MDSC and T regulatory cells, and on modulation of peripheral and intra-tumoral T cell populations. Combinations of Rosiglitazone and Gemcitabine significantly reduced tumor progression and metastases, enhanced apoptosis, and significantly extended overall survival compared to Gemcitabine alone. Rosiglitazone altered tumor-associated immune suppressive mediators by limiting early MDSC accumulation and intra-tumoral T regulatory cells. Combination therapy with Rosiglitazone and Gemcitabine modulated T cell populations by enhancing circulating CD8
Introduction
Pancreatic cancer is accompanied by inflammation and the induction of significant immune suppression, through the accumulation of myeloid-derived suppressor cells (MDSC) and T regulatory cells [1, 2] , which enables tumor progression and serves as a significant impediment to successful immunotherapy. Pre-clinical studies demonstrate that elimination of mediators of immunosuppression, either directly or by limiting tumor-associated inflammation, significantly improves anti-tumor immune responses and increases apoptosis in a pancreatic cancer model [3] . Although Gemcitabine has been shown to limit MDSC accumulation [4] , this reduction is transient and Gemcitabine does not effectively limit T regulatory cells in pancreas cancer [3] , highlighting the need for additional therapies that can be effectively combined with Gemcitabine to target inflammation and immune suppression.
Peroxisome proliferator-activated receptor gamma (PPARc) is a critical regulator of inflammation and cellular differentiation. Loss-of-function mutations in the PPARc gene are present in some human colon cancers [5] , and PPARc ?/-mice have an increased susceptibility to tumor development in several organs [6] , suggesting a role for PPARc as a tumor suppressor. Activation by synthetic ligands in the thiazolidinediones class, such as Rosiglitazone, limits tumor cell growth in murine and human cancer cell lines, including pancreatic cancer cell lines [7] , and limits tumor progression [7] [8] [9] [10] and inflammatory conditions in vivo [11, 12] . Several epidemiological studies show a decreased incidence of neoplasms in the general population and diabetic patients taking thiazolidinediones [13, 14] . PPARc ligands showed growth retardation and differentiation effects on liposarcoma [15] and a stabilization of PSA levels in prostate cancer patients [16] .
Despite pre-clinical efficacy, translation of these drugs into clinical trials as single agents has met with limited success, and evidence suggests that these agents may be better as adjuncts to standard therapy. Rosiglitazone enhances Gemcitabine cytotoxicity in pancreas cancer cell lines [17, 18] and fluoracil-induced apoptosis in colon cancer cell lines [19] . Several molecular mechanisms have been proposed for the evident synergy between Rosiglitazone and Gemcitabine; however, regulation of the immune system has not been examined as combination treatments have not been evaluated in vivo in an immunocompetent model. The anti-inflammatory effects of PPARc, mediated through a reduction in inflammatory cytokines [20] , suggested to us that PPARc activation may regulate immune suppressive mechanisms, such as T regulatory cells and MDSC, which are induced by tumorassociated inflammation. Additionally, activation of PPARc has been shown to promote myeloid differentiation [20] possibly limiting the accumulation of MDSC and evidence shows that PPARc agonists can alleviate macrophage suppression of cytotoxic T lymphocytes [21] , further suggesting that targeting PPARc may diminish tumorassociated suppressive mechanisms.
We evaluated the effects of PPARc agonists in the context of Gemcitabine treatment of pancreatic cancer and found that high doses of Rosiglitazone in combination with Gemcitabine limited tumor progression and invasion and enhanced survival in an immunocompetent murine model of pancreatic cancer. PPARc activation limited early accumulation of MDSC and modulated the immune suppressive tumor microenvironment by decreasing intratumoral T regulatory cells and increasing both peripheral CD8
? T cells and intra-tumoral CD4 ? and CD8 ? T cells.
Materials and methods

Mice, cell lines, and reagents
Six-to eight-week-old C57BL6 mice were obtained from the Jackson Laboratories (Bar Harbour, ME), and all animal procedures were approved by the UNMC Institutional Animal Care and Use Committee. The Panc02 carcinoma cell line was maintained in McCoy's 5A medium (Cellgro, Manassas, VA) supplemented with 10 % FBS and 1 % antibiotic-antimycotic solution (Cellgro). Rosiglitazone (Sigma, St. Louis, MO) was resuspended in DMSO. For animal studies, Rosiglitazone was reconstituted in 100 % EtOH and Pioglitazone was reconstituted in DMSO, and both were dissolved at the indicated concentrations in sterile drinking water. Gemcitabine (38 mg/ml; Lilly, Indianapolis, IN), Rosiglitazone Maleate (Avandia, GlaxoSmithKline), and Pioglitazone HCL (Actos, Takeda Pharmaceuticals) were obtained through the UNMC pharmacy. Supernatants from hybridomas expressing an antibody against CD25 (PC61) and control rat IgG antibody (UC7) were purified by the monoclonal facility at UNMC.
Tumor inoculations
For subcutaneous injections, 1 9 10 6 Panc02 cells were trypsinized, washed, resuspended in 50 ll of sterile PBS and injected into the flank of C57BL6 mice. Tumor growth was monitored weekly by measuring tumor diameter using a caliper, and survival time indicates the number of days until tumors reached 1 cm 2 and mice were euthanized. For orthotopic implantations, 5 9 10 5 Panc02 cells were prepared as described for subcutaneous injections, resuspended in 30 ll of sterile PBS and implanted into the pancreas as described previously [22, 23] . For orthotopic experiments, mice were euthanized and tumor volume was calculated when tumors greater than 1 cm 3 were palpable or control mice appeared moribund. In the Gemcitabinetreated group, mice were injected i.p. with Gemcitabine (60 mg/kg) twice a week every other week. Mice treated with Rosiglitazone or Pioglitazone were given drug in the drinking water at final concentrations of 100 lM or 1 mM. Water consumption studies in adult mice (20-40 g ) have consistently shown that individual mice consume 15 ml of water/100 g/day. This translates into administration of Rosiglitazone at approximately 7.2 and 72 mg/kg/day at concentrations of 100 lM and 1 mM, respectively. Tumor diameters (2/tumor) were measured weekly, and tumor volume was calculated (V = 4/3*p*r 3 ). Ascites was evaluated as the presence or absence of fluid in the peritoneal cavity, and peritoneal metastases were considered present when [5 nodules were visible.
In vitro growth and invasion assays For in vitro cell proliferation assays, 1 9 10 5 Panc02 cells were plated in 6-well plates in 3 ml of growth media, serumfree media, or growth media supplemented with Rosiglitazone or Pioglitazone (10 lM or 100 lM). Cells were counted microscopically at 24, 48, and 72 h. For invasion assays, 2 9 10 4 Panc02 cells were seeded into the upper chamber of a Biocoat Matrigel Invasion Chamber (BectonDickinson, Bedford, MA) in serum-free media. The lower chamber contained medium alone or supplemented with Rosiglitazone (10 or 100 lM). The chambers were cultured at 37°C for 24 h. Cells invading to the bottom of the membrane were fixed and stained with Diff-Quick staining kit (Allegiance) and quantified at 2009 magnification by light microscopy as previously described [22] .
Western blotting Panc02 cells, untreated or treated with the indicated drug concentrations, were lysed in RIPA cell lysis buffer (150 mM sodium chloride, 1 % IGEPAL Ca-630, 0.5 % sodium deoxycholate, 0.1 % SDS, 50 nM Tris) with protease inhibitors (complete mini inhibitor cocktail, Roche, Manheim, Germany) and 1 mM PMSF. One hundred micrograms of protein, as determined by Bradford assay, was boiled and reduced with 0.1 M DTT and run on a 4-20 % Tris/Glycine polyacrylamide gel (Bio-Rad, Hercules, CA) as described previously [24, 25] and transferred to PVDF. Membranes were blocked for at least 1 h and stained in 5 % milk. Anti-TGFb1 antibody (Santa Cruz) and anti-cleaved caspase 3 (Cell Signaling) were used at 1:100 and 1:500, respectively. All membranes were stripped (0.2 M NaOH) and probed with anti-b-actin antibody at 1:5,000 (Sigma) as a protein loading control. 
Flow cytometry
White blood cells were collected by submandibular bleeding of C57BL6 tumor-bearing mice, and red blood cells were lysed in lysis buffer (154 mM NH 4 Cl, 10 mM KHCO 3 , 0.1 mM EDTA) for 10 min at room temperature followed by centrifugation for 5 min at 1200 rpm. Remaining white blood cells were labeled by direct immunofluorescence with antibodies against Gr1, CD11b, CD3, CD4, CD8, and CD25 (BD Pharmingen, San Diego, CA) as previously described [26] .
Statistical analyses
All analyses were conducted using analysis of variance after performing a rank transformation on the variables. Post hoc comparisons and data were analyzed using repeated measures ANOVA with a Tukey adjustment for multiple comparisons. Survival analysis was calculated using the Kaplan and Meier method, and outcomes were analyzed using a log-rank test.
Results
Rosiglitazone and Pioglitazone limit cell proliferation in vitro
Thiazolidinediones have been shown to reduce proliferation of several human pancreatic cancer cell lines [10, 27] , and Rosiglitazone limits in vitro tumor cell growth in several murine and human cell lines (reviewed in [28] ). We evaluated the capacity of Rosiglitazone and Pioglitazone to reduce the growth of a murine pancreatic adenocarcinoma cell line, Panc02. Tumor cells were grown in serum-free media, culture media (10 % FBS), either alone or supplemented with Rosiglitazone or Pioglitazone at 10 and 100 lM, and cells were counted at 24, 48, and 72 h (Fig. 1a) . A dose-dependent reduction in Panc02 cell proliferation was observed, with a [3.5-fold reduction in growth with Rosiglitazone 100 lM treatment. Similarly, Pioglitazone at both 10 and 100 lM also significantly reduced Panc02 cell proliferation, demonstrating that both thiazolidinediones can reduce pancreatic cancer cell growth in vitro. This reduction in cell growth was not due to increased apoptosis, as no increase in cleaved caspase 3 was detected after Rosiglitazone treatment (10 and 100 lM) (Fig. 1b) .
Combination of Rosiglitazone and Gemcitabine limits tumor progression and increases survival
The synergy of some thiazolidinediones with chemotherapeutic agents in vitro suggested that Rosiglitazone or Pioglitazone may enhance the efficacy of Gemcitabine in vivo. We evaluated the effects of combinations of either Rosiglitazone or Pioglitazone with Gemcitabine on tumor progression in pancreatic cancer. C57BL6 mice were inoculated subcutaneously with Panc02 cells and tumor diameter was measured weekly. Mice were either untreated, treated continuously with Rosiglitazone or Pioglitazone at either 100 lM or 1 mM in the drinking water, treated with Gemcitabine (60 mg/kg; twice weekly, every other week) or combination treatments. Pioglitazone or Rosiglitazone (100 lM or 1 mM) alone did not significantly affect tumor progression and Pioglitazone at either concentration in combination with Gemcitabine was not more effective than Gemcitabine alone (Pioglitazone at 1 mM data not shown), suggesting that Pioglitazone did not have an effect on tumor progression in vivo. However, higher doses of Rosiglitazone with Gemcitabine led to significantly reduced tumor growth (p \ 0.05) with the reduction being most significant at 100 lM or greater doses of Rosiglitazone (Fig. 1c) . The observed decrease in tumor growth was associated with an increase in overall survival (defined as the day post-tumor inoculation when tumors reached 1 cm 3 and mice were euthanized). Overall survival was significantly extended by the combination treatment compared to untreated and Gemcitabine-treated mice (p = 0.003) (Fig. 1d volume was measured. Similar to the results observed in the subcutaneous tumor growth experiment, treatment with Gemcitabine resulted in significantly reduced tumor volume (p = 0.03), whereas treatment with Rosiglitazone alone had no statistically significant effect, although there was a trend for decreased tumor volume in this group (Fig. 2a) . However, combination treatment using Rosiglitazone 1 lM showed significantly reduced tumor volumes compared to untreated (p \ 0.0001) and Gemcitabine alone (p = 0.009). In addition to reducing tumor burden, only 80 % of the mice treated with Rosiglitazone (1 mM) and Gemcitabine had pancreatic tumors compared to 100 % for all other groups (data not shown). Rosiglitazone alone had no effect on the percentage of mice with tumor. Since Rosiglitazone and Gemcitabine showed increased caspase 3 expression and apoptosis activity in vitro (data not shown), we examined whether the decreased tumor volume was correlated with increased apoptosis. Paraffinembedded tumor sections from Panc02 tumor-bearing mice treated with single and combination agents were stained by immunohistochemistry for the expression of cleaved caspase 3. Tumors from Gemcitabine-treated mice showed increased numbers of apoptotic cells; however, this increase was not statistically significant (Fig. 2b ). Mice treated with Rosiglitazone (100 lM) and Gemcitabine had significantly higher numbers of caspase 3 positive apoptotic cells (p = 0.014).
Tumor growth inhibition by treatment with Rosiglitazone and Gemcitabine was accompanied by a reduction in peritoneal invasion and metastasis as determined by evaluating mice for ascites and numbers of peritoneal nodules. Rosiglitazone alone had no effect on the presence of ascites (Fig. 2c) , the development of peritoneal nodules (Fig. 2c) , or the percent of mice with splenic invasion (data not shown). Although Gemcitabine alone reduced the percent of mice with ascites by eightfold, Gemcitabine alone did not have a significant effect on any other parameter evaluated. The addition of Rosiglitazone to Gemcitabine, particularly at the 1 mM concentration, reduced the percentage of mice with peritoneal nodules by 50 % (Fig. 2c ). These results demonstrate that the combination of Rosiglitazone and Gemcitabine limits orthotopic tumor growth and reduces peritoneal invasion and metastasis. We also observed a reduction in invasive properties in vitro following treatment with Rosiglitazone (Fig. 2d) . Rosiglitazone treatment led to a dose-dependent reduction in Panc02 cell invasion (a 5-11-fold decrease in invasion with 100 lM Rosiglitazone).
Rosiglitazone reduces early levels of CD11b ? Gr1 high MDSC Pancreatic cancer is accompanied by significant immune suppression, mediated in part by the accumulation of MDSC and T regulatory cells [1, 2] . It is well documented that inflammation, which accompanies pancreatic tumor progression, induces the accumulation of MDSC [29] and T regulatory cells. To establish the anti-inflammatory properties of Rosiglitazone, tumor sections from orthotopic Panc02 tumor-bearing mice untreated or treated with Gemcitabine, Rosiglitazone, or a combination of both were stained by immunohistochemistry with antibodies against TGFb and COX-2 (Fig. 3a) . Immunohistochemical staining of COX-2 and TGFb demonstrates that Rosiglitazone limits TGFb and COX-2 expression in the tumor microenvironment, suggesting that the anti-inflammatory properties of PPARc may limit inflammation, in turn reducing the expansion of MDSC. Since Gemcitabine has also been shown to limit MDSC in vivo [4] , we examined whether Rosiglitazone would further reduce the MDSC burden, and whether this reduction contributes to the observed reduction in tumor progression. Orthotopic Panc02 tumor-bearing mice were bled through the submandibular vein at 1, 3, and 5 weeks after tumor implantation (with the first week being preGemcitabine treatment). Circulating mononuclear cells were stained with antibodies to Gr1 and CD11b to analyze the percent of blood MDSC by flow cytometry. Rosiglitazone significantly decreased blood CD11b
? Gr1 high MDSC levels compared to untreated mice at week 1 and week 3 (p = 0.02 and p = 0.01, respectively) and MDSC levels were similar in both Rosiglitazone-treated and Gemcitabine-treated mice at the early stages of tumor growth (Fig. 3b) , although Rosiglitazone appeared more slightly more effective than
Gr1
high MDSC levels in Rosiglitazone-treated mice rebounded to levels comparable to untreated mice, while CD11b ?
high MDSC levels remained low in Gemcitabine-treated mice. These results suggest that Rosiglitazone can initially suppress the accumulation of CD11b 
high MDSC levels expand despite the Rosiglitazone treatment and Rosiglitazone does not enhance the Gemcitabine-mediated suppression of MDSC.
Rosiglitazone reduces TGFb production and limits intra-tumoral infiltration of T regulatory cells
The anti-inflammatory effects of PPARc activation result in part from the transrepression of NFjB leading to a decrease in a wide array of inflammatory cytokines, including TGFb [20] . Rosiglitazone treatment decreased in vitro TGFb production by Panc02 cells in a dose-dependent manner, as seen by the reduction in expression of the 12 kDa monomer (Fig. 3c) . To determine whether this decrease was associated with alterations in the accumulation of intra-tumoral T regulatory cells in vivo, paraffinembedded sections of orthotopic Panc02 tumors from mice either untreated or treated with Rosiglitazone, Gemcitabine, or both were stained by immunofluorescence with FITC-labeled FoxP3, a T regulatory cell marker (Fig. 3d) . Treatment of tumor-bearing mice with Rosiglitazone alone significantly decreased the number of intra-tumoral FoxP3
? T regulatory cells (p = 0.003), while Gemcitabine had no effect (Fig. 3d ). These results demonstrate that Rosiglitazone treatment limited TGFb production from Panc02 cells and reduced the intra-tumoral infiltration of immune suppressive T regulatory cells.
In vivo depletion of T regulatory cells reduces tumor progression but does not enhance the effects of Rosiglitazone and Gemcitabine therapy
Since the reduction in tumor progression in Rosiglitazoneand Gemcitabine-treated mice is accompanied by a decrease in the number of infiltrating T regulatory cells, we asked whether depletion of T regulatory cells would further enhance this effect. Panc02 cells were orthotopically implanted into the pancreas of C57BL6 mice, and the following treatments were started 1 week post-implantations: a control rat IgG antibody or an antibody against CD25 (PC61) to deplete T regulatory cells; Gemcitabine with or without PC61 or rat IgG; Rosiglitazone and Gemcitabine with or without PC61 or rat IgG. Mice were euthanized when control mice became moribund. PC61 and rat IgG antibody (0.5 mg) were given on day -4, -2, ?1, and every 2 weeks for the duration of the experiment. Leukocytes obtained from weekly bleeds were doublestained with antibodies against CD4 ? and CD25 ? to ensure T regulatory cell depletion in PC61-treated mice. Compared to rat IgG-treated mice, PC61-treated mice had a significant reduction in circulating CD4
? CD25 ? T regulatory cells (Fig. 4a) . Treatment with PC61 significantly reduced tumor volume compared to rat IgG-treated mice (p \ 0.0001); however, tumors were not significantly smaller than Gemcitabine alone and tumor volumes were significantly larger than Rosiglitazone and Gemcitabinetreated mice (p = 0.003) (Fig. 4b) . The addition of PC61 treatment to Rosiglitazone and Gemcitabine did not reduce tumor volumes compared to control Rosiglitazone and Gemcitabine-treated mice, suggesting that targeted CD4
? CD25 ? T regulatory cell depletion did not further enhance the effects of this combination treatment, and supporting our conclusion that the inhibition of tumor progression we observed was due in part to blocking of T regulatory activity.
Rosiglitazone and Gemcitabine treatment increases both peripheral CD3
? CD8 ? T cells and intra-tumoral infiltration of CD4
? and CD8 ? T cells
The reduction in tumor progression observed in mice treated with Rosiglitazone and Gemcitabine may result from enhanced T cell responses, either due to a decrease in the presence of T regulatory cells in Rosiglitazone-and Gemcitabine-treated mice, or as a result of enhanced proliferation and recruitment of effector T cell populations. We evaluated the effects of depletion of T regulatory cells on numbers of peripheral CD3
? CD8 ? T cells. Gemcitabine, Rosiglitazone, and PC61 treatment did not alter the percentage of circulating CD3
? CD8 ? T cells, which decreased significantly after week 1 when tumors became established (Fig. 4c) . Only Rosiglitazone and Gemcitabine combination-treated mice showed a significant recovery of peripheral CD3
? CD8 ? T cells compared to rat IgG-treated mice as tumors progressed (p = 0.03). We also evaluated treated mice for tumor infiltration by T cells. Paraffin-embedded tumor sections from the same orthotopic treated mice were stained by immunofluorescence to FITC-labeled CD4
? , CD8
? and FoxP3 ? . As discussed previously, Rosiglitazone treatment reduced the number of tumor infiltrating FoxP3 ? T regulatory cells and this reduction was equivalent to the reduction seen with PC61 treatment (Fig. 4d) , suggesting that Rosiglitazone effectively depletes T regulatory cells from the tumor milieu. Although Rosiglitazone alone did not alter the percent of peripheral CD8
? T cells (Fig. 4c) , there was a significant increase in the number of CD8 ? tumor infiltrating T cells (p = 0.05) (Fig. 4d) . The combination of Rosiglitazone and Gemcitabine led to a significant increase in both CD4
? and CD8 ? T cell infiltration and a significant decrease in FoxP3 ? infiltration. These results suggest that Rosiglitazone and Gemcitabine significantly alter the intra-tumoral lymphocyte populations and skew toward more favorable immune effector populations.
Discussion
Pre-clinical [7] [8] [9] [10] and epidemiological [13, 14] evidence suggests that activation of PPARc results in synergy with chemotherapeutic agents that may reduce tumor burden in pancreatic cancer. Despite this preliminary evidence, PPARc agonists have not been assessed in the context of chemotherapy for pancreatic cancer. These combination therapies have been examined mostly in vitro and a few in vivo studies to date have been performed in immune deficient animal models, which would not detect effects on tumor immunity. We report here that PPARc agonist, Rosiglitazone, when combined with Gemcitabine limited pancreatic tumor progression and extended survival in a mouse model in part by modulating immune suppressive cellular mediators, such as MDSC and T regs, and altering peripheral and intra-tumoral T cell populations.
Previous evidence of synergy between Rosiglitazone and Gemcitabine is derived primarily from in vitro work; hence, our studies are among the first to evaluate this synergy in the context an active anti-tumor immune response. It is established that Rosiglitazone enhances Gemcitabine-mediated apoptosis through several possible mechanisms, such as negative regulation of the AKT/ PTEN pathway [30, 31] , induction of cancer cell differentiation [15] and/or suppression of angiogenesis [32] . Similarly, our in vivo data support the hypothesis that an increase in apoptosis may result from the combination of these two agents, although the observed increase in apoptosis in vivo as measured by caspase 3 activation may also be a result of the increased intra-tumoral infiltration of T cells and the reduction in immune suppressive T regulatory cells observed in the combination-treated group. Our data demonstrate a significant increase in apoptosis in the primary tumor in the presence of Rosiglitazone alone, suggesting that this increase is not due completely to synergy between Rosiglitazone and Gemcitabine. Additionally, in the Rosiglitazone-treated animals, we observed a decrease in T regulatory cell infiltration and an increase in CD8
? T cell infiltration, suggesting that the increase in apoptosis seen in this group may be a result of the altered immune cell infiltrates. Although a trend for reduced tumor size was observed in the Rosiglitazone-treated group, these changes did not result in a significant reduction in tumor progression in the absence of Gemcitabine, highlighting the potential synergy between these two agents.
It is well documented that inflammation promotes and accompanies tumor progression in pancreatic cancer and is a significant impediment to therapy. Reducing inflammation through the use of non-steroidal anti-inflammatory drugs (NSAIDs) has been linked to a decrease in pancreatic cancer risk [33] , a decrease in pancreatic cancer cell proliferation in vitro [34, 35] , and good clinical benefit in a Phase II trial evaluating NSAID use in combination with Gemcitabine [36] , supporting the concept that a reduction in inflammation in the context of chemotherapy may enhance current treatment options. In addition to enhancing angiogenesis and the growth factor milieu, inflammatory mechanisms promote tumor-associated immune suppression, through the induction of MDSC [29, 37] and T regulatory cells [38] , further limiting anti-tumor immunity. A major function of PPARc activation is to limit the inflammatory environment through several pathways, including transrepression of NFjB and STATs, thereby significantly modulating the tumor microenvironment [20, 39] . PPARc activation has been shown to limit inflammation in a model of inflammatory bowel disease (IBD), supporting the use of PPARc ligands as anti-inflammatory agents [12] . Rosiglitazone has been shown to limit the production of inflammatory prostaglandin E2 (PGE2) [40] , a major inducer of both MDSC [37] and T regulatory cells [41] . Our data demonstrate that at the early stages of tumor growth (up to week 3), Rosiglitazone limits blood accumulation of CD11b
? Gr1 high MDSC to levels similar to those seen with Gemcitabine treatment. This reduction in peripheral MDSC may be due to a reduction in inflammatory mediators or a maturation of this immature cell population, as PPARc activation leads to maturation of myeloid lineage cells [20] . As tumors progress into late stages of growth (week 5), CD11b expansion was equivalent to that seen in untreated mice; however, this delay in MDSC expansion may enhance the capacity of early anti-tumor immunity. Both Rosiglitazone and Gemcitabine can limit early CD11b ? Gr1 high MDSC; however, combination therapy does not further limit accumulation of these cells, suggesting that maximal inhibition of MDSC has been achieved with either agent alone. Additionally, we show that Rosiglitazone treatment limits T regulatory cell accumulation in the primary tumor, which may also boost anti-tumor functions. Since MDSC can induce T regulatory cells through the production of TGFb, the reduction in MDSC by Rosiglitazone may also lead to the observed reduction in T regulatory cells. The reduction in both of these suppressive populations may enhance anti-tumor immunity by limiting peripheral and intra-tumoral T cell suppression leading to a reduction in tumor progression.
We observed that T regulatory cell depletion with PC61 or combination therapy with Gemcitabine and Rosiglitazone significantly limited tumor growth; however, the triple combination of these treatments was not additive, but rather less effective in reducing tumor burden. A possible explanation for this finding is that treatment with PC61 or Rosiglitazone and Gemcitabine was shown to specifically reduce intra-tumoral FoxP3
? T regulatory cells and to increase peripheral and intra-tumoral CD8
? T cells; however, because PC61 specifically targets CD25
? T cells, PC61 may also be depleting CD25
? effector T cells. These data suggest that a reduction in T regulatory cells and a recovery of CD8
? T cells are essential components to the anti-tumor effect of Rosiglitazone and Gemcitabine therapy.
Our in vivo data in the subcutaneous model suggested that Rosiglitazone alone was ineffective as a single agent and that both concentrations of Rosiglitazone (100 lM and 1 mM) were effective in combination with Gemcitabine. Rosiglitazone alone did not significantly alter tumor size in the orthotopic model; however, there was a trend toward reduced tumor size, and the 1 mM Rosiglitazone concentration was significantly more effective in combination with Gemcitabine. In this context, it is important to consider the dose and schedule of Rosiglitazone we utilized, as this differs from that of current clinical practice. Rosiglitazone is administered at 4-8 mg/day as a single or divided dose to humans, which corresponds to 0.04-0.15 mg/kg. Given that mice consume 15 ml of water/100gm/day, we delivered Rosiglitazone to mice at approximately 7.2 and 72 mg/kg/day at concentrations of 100 lM and 1 mM in drinking water, respectively. These significantly higher doses (50-500 times that used in humans) were achieved without toxicity, presumably in part because the continuous administration in drinking water allowed for higher daily dose. The dose and schedule of administration may explain in part our results, although confirmation of this hypothesis should be obtained by careful pharmacokinetic analyses and additional studies of dose and schedule. It is possible that the prolonged administration of drug in drinking water affected the immune cells or tumor cells through continuous activation of PPARc and that the net effect was different from exposure to a bolus of drug from a single administration. Moreover, drug delivery in pancreatic cancer is a significant impediment to chemotherapy, and there are differences in vascular content and stromal content in subcutaneous and orthotopic animal models that impact the ability of these agents to reach the growing tumor and synergize effectively. Although the administration of Rosiglitazone and Gemcitabine were identical in both subcutaneous and orthotopic models, the delivery of these drugs to tumor undoubtedly varies based on the tumor location and stromal content, which may explain why higher doses were more effective at the orthotopic site. It will be important in the future to investigate this drug combination in appropriate genetically engineered models of pancreatic cancer, which may better reflect typical poorly vascularized conditions encountered in human pancreatic cancer.
The link between pancreatic cancer and diabetes is not well understood, although it is estimated that 80 % of pancreatic cancer patients are intolerant to glucose or have diabetes [42] . Insulin and glucose production have been shown to promote cancer cell growth and contribute to chemoresistance, suggesting that management of these diabetic symptoms may enhance the efficacy of chemotherapy regiments [17] . Epidemiological data suggest that the survival of diabetic cancer patients may vary based on the anti-diabetic treatments, and certain treatments, such as Rosiglitazone, have been shown to enhance Gemcitabine apoptosis and overcome chemoresistance in vitro while other anti-diabetic drugs do not exhibit the same therapeutic effects [17] . We demonstrate here that both Pioglitazone and Rosiglitazone were effective at similar concentrations in limiting cell proliferation in vitro; however, only Rosiglitazone in combination with Gemcitabine had a therapeutic effect in vivo. The differences between these two agents of the same thiazolidinedione class and their ability to synergize with Gemcitabine are currently unclear. Reports examining these two drugs in diabetic patients note differential effects on serum lipoprotein profile; however, to our knowledge other parameters that may invoke anti-tumor effects have not been examined. One possibility for distinct effects in vivo may be due to potency, as Pioglitazone has been show to be ten times less potent in PPARc activation than Rosiglitazone and less selective as it also enhances PPARa activity [43] . In our model, Pioglitazone and Rosiglitazone alone at the 1 mM concentration had similar effects on tumor growth rate. The different specificities for the PPAR receptors may also result in different vascular effects as Pioglitazone has been shown to increase VEGF and angiogenin, which stimulate new vasculature formation, compared to Rosiglitazone [44] . Pioglitazone has been shown to increase TGFb production [45] , which is in contrast to our data demonstrating that Rosiglitazone limits TGFb production. It is notable that there are low-level toxicities associated with prolonged use of Rosiglitazone, which has led to a substitution of Pioglitazone in clinical applications. In the context of treating pancreatic cancer, the toxicities associated with high doses of Rosiglitazone should be considered, but it remains possible that these toxicities will show a degree of specificity for modulating immunosuppression and pancreatic tumor growth, in which case they may be clinically useful. It may be possible to minimize undesirable toxicities from higher total doses by use of an appropriate schedule of administration. Moreover, if a major beneficial effect of Rosiglitazone in combination with Gemcitabine is a modulation of immunosuppression, then it might be possible and desirable to combine appropriate doses and schedules of this strategy with targeted immunotherapies.
In conclusion, this study examined the potential therapeutic effect of PPARc activation, through Rosiglitazone, in combination with Gemcitabine in the treatment of pancreatic cancer. To our knowledge, this is the first report to evaluate this combination therapy in an immune competent animal model of pancreatic cancer and to characterize the effects of these agents on immune suppressive mechanisms. Our study demonstrates that Rosiglitazone, an FDA-approved anti-diabetic agent, in combination with Gemcitabine, resulted in a significant downregulation of immune suppressive mechanisms and modulation of the T cell tumor microenvironment to a more favorable cellular content for tumor rejection, and that this slightly prolonged survival of immunocompetent mice challenged with pancreatic cancer. There is merit in further exploring the efficacy of this combination in the pre-clinical and perhaps the clinical setting for the treatment of pancreatic cancer.
